Literature DB >> 14563355

Cytokine regulation of pulmonary fibrosis in scleroderma.

Sergei P Atamas1, Barbara White.   

Abstract

Pulmonary fibrosis occurs in up to 70% of scleroderma patients and progresses to cause severe restrictive lung disease in about 15% of patients. The mechanisms that cause pulmonary fibrosis in scleroderma remain incompletely understood. Increased amounts of mRNA or protein for multiple profibrotic cytokines and chemokines have been identified in lung tissue or broncholveolar lavage samples from scleroderma patients, when compared to healthy controls. These cytokines include transforming growth factor (TGF)-beta, connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF), oncostatin M (OSM), monocyte chemotactic factor-1 and pulmonary and activation-regulated chemokine (PARC). Potential cellular sources of these profibrotic cytokines and chemokines in scleroderma lung disease include alternatively activated macrophages, activated CD8+ T cells, eosinophils, mast cells, epithelial cells and fibroblasts themselves. This review summarizes the literature on involvement of cytokines and chemokines in the development of pulmonary fibrosis in scleroderma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14563355     DOI: 10.1016/s1359-6101(03)00060-1

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  50 in total

1.  Serum concentrations of cyclooxygenase-2 in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis.

Authors:  Iman H Bassyouni; Roba M Talaat; Tarek A Salem
Journal:  J Clin Immunol       Date:  2011-10-07       Impact factor: 8.317

Review 2.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

3.  A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

Authors:  Arnold E Postlethwaite; Weng Kee Wong; Philip Clements; Soumya Chatterjee; Barri J Fessler; Andrew H Kang; Joseph Korn; Maureen Mayes; Peter A Merkel; Jerry A Molitor; Larry Moreland; Naomi Rothfield; Robert W Simms; Edwin A Smith; Robert Spiera; Virginia Steen; Kenneth Warrington; Barbara White; Frederick Wigley; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06

Review 4.  Myeloid Populations in Systemic Autoimmune Diseases.

Authors:  María Morell; Nieves Varela; Concepción Marañón
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

Review 5.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

6.  Interleukins 4 and 13 modulate gene expression and promote proliferation of primary human tenocytes.

Authors:  Jean-Paul Courneya; Irina G Luzina; Cynthia B Zeller; Jeffrey F Rasmussen; Alexander Bocharov; Lew C Schon; Sergei P Atamas
Journal:  Fibrogenesis Tissue Repair       Date:  2010-06-10

7.  Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays.

Authors:  Anders Carlsson; Dirk M Wuttge; Johan Ingvarsson; Anders A Bengtsson; Gunnar Sturfelt; Carl A K Borrebaeck; Christer Wingren
Journal:  Mol Cell Proteomics       Date:  2011-02-24       Impact factor: 5.911

8.  Caveolin-1 deficiency may predispose African Americans to systemic sclerosis-related interstitial lung disease.

Authors:  Charles Reese; Beth Perry; Jonathan Heywood; Michael Bonner; Richard P Visconti; Rebecca Lee; Corey M Hatfield; Richard M Silver; Stanley Hoffman; Elena Tourkina
Journal:  Arthritis Rheumatol       Date:  2014-07       Impact factor: 10.995

9.  Macrophages produce TGF-beta-induced (beta-ig-h3) following ingestion of apoptotic cells and regulate MMP14 levels and collagen turnover in fibroblasts.

Authors:  Natalia Nacu; Irina G Luzina; Kendrick Highsmith; Virginia Lockatell; Kerill Pochetuhen; Zachary A Cooper; Michael P Gillmeister; Nevins W Todd; Sergei P Atamas
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

10.  Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.

Authors:  Katrin Schmidt; Lorena Martinez-Gamboa; Susan Meier; Christian Witt; Christian Meisel; Leif G Hanitsch; Mike O Becker; Doerte Huscher; Gerd R Burmester; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2009-07-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.